| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Accidental Falls | 15 | 2017 | 145 | 4.570 |
Why?
|
| Accidents, Occupational | 13 | 2016 | 55 | 3.380 |
Why?
|
| Restaurants | 13 | 2015 | 28 | 3.380 |
Why?
|
| Water Pollutants, Chemical | 5 | 2023 | 33 | 2.730 |
Why?
|
| Shoes | 8 | 2015 | 21 | 1.580 |
Why?
|
| Oxadiazoles | 2 | 2021 | 7 | 1.500 |
Why?
|
| Cell Fusion | 5 | 2024 | 43 | 1.390 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 6 | 2021 | 48 | 1.270 |
Why?
|
| Anti-Bacterial Agents | 3 | 2024 | 694 | 1.240 |
Why?
|
| Workplace | 9 | 2019 | 179 | 1.230 |
Why?
|
| Osteoclasts | 3 | 2018 | 50 | 1.220 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 3 | 2024 | 62 | 1.220 |
Why?
|
| Structure-Activity Relationship | 8 | 2024 | 371 | 1.130 |
Why?
|
| Drug Design | 3 | 2024 | 143 | 1.110 |
Why?
|
| Molecular Docking Simulation | 9 | 2024 | 77 | 1.100 |
Why?
|
| Enzyme Inhibitors | 2 | 2019 | 332 | 1.060 |
Why?
|
| Aerosols | 6 | 2022 | 44 | 1.050 |
Why?
|
| Wounds and Injuries | 4 | 2018 | 235 | 1.040 |
Why?
|
| Leisure Activities | 2 | 2015 | 31 | 0.990 |
Why?
|
| Environmental Monitoring | 7 | 2023 | 138 | 0.990 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2024 | 7 | 0.980 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2024 | 11 | 0.980 |
Why?
|
| Oral Health | 2 | 2023 | 73 | 0.970 |
Why?
|
| Antitubercular Agents | 3 | 2024 | 68 | 0.960 |
Why?
|
| Occupational Injuries | 6 | 2015 | 37 | 0.950 |
Why?
|
| Trophoblasts | 1 | 2024 | 7 | 0.950 |
Why?
|
| Low Back Pain | 8 | 2013 | 120 | 0.950 |
Why?
|
| Giant Cells | 1 | 2024 | 17 | 0.950 |
Why?
|
| Humans | 72 | 2024 | 58815 | 0.930 |
Why?
|
| Janus Kinase Inhibitors | 1 | 2024 | 16 | 0.910 |
Why?
|
| Employment | 5 | 2014 | 135 | 0.900 |
Why?
|
| Spike Glycoprotein, Coronavirus | 2 | 2024 | 97 | 0.900 |
Why?
|
| Antineoplastic Agents | 3 | 2024 | 634 | 0.900 |
Why?
|
| Malocclusion, Angle Class II | 2 | 2013 | 2 | 0.890 |
Why?
|
| Tooth Injuries | 1 | 2023 | 2 | 0.880 |
Why?
|
| Environmental Restoration and Remediation | 1 | 2023 | 6 | 0.880 |
Why?
|
| Rubella | 1 | 2023 | 5 | 0.880 |
Why?
|
| Mumps | 1 | 2023 | 7 | 0.870 |
Why?
|
| Measles | 1 | 2023 | 8 | 0.870 |
Why?
|
| Air Pollutants | 4 | 2022 | 84 | 0.870 |
Why?
|
| Facial Injuries | 1 | 2023 | 14 | 0.870 |
Why?
|
| Nanotubes, Carbon | 1 | 2023 | 20 | 0.870 |
Why?
|
| Disability Evaluation | 6 | 2013 | 212 | 0.840 |
Why?
|
| Comprehension | 1 | 2023 | 122 | 0.820 |
Why?
|
| Quantitative Structure-Activity Relationship | 5 | 2022 | 11 | 0.790 |
Why?
|
| Water Purification | 1 | 2021 | 6 | 0.780 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2021 | 28 | 0.770 |
Why?
|
| Accidents, Traffic | 3 | 2018 | 150 | 0.750 |
Why?
|
| Nanocomposites | 1 | 2021 | 28 | 0.750 |
Why?
|
| Mycobacterium tuberculosis | 3 | 2024 | 374 | 0.740 |
Why?
|
| Middle East Respiratory Syndrome Coronavirus | 1 | 2020 | 2 | 0.730 |
Why?
|
| Nanoparticles | 3 | 2021 | 489 | 0.730 |
Why?
|
| Viruses | 1 | 2021 | 79 | 0.730 |
Why?
|
| Adolescent | 23 | 2018 | 5857 | 0.720 |
Why?
|
| Particulate Matter | 3 | 2021 | 59 | 0.710 |
Why?
|
| Adult | 36 | 2023 | 15611 | 0.710 |
Why?
|
| Extracellular Vesicles | 1 | 2020 | 39 | 0.710 |
Why?
|
| Sialic Acids | 1 | 2020 | 46 | 0.700 |
Why?
|
| Occupational Health | 5 | 2019 | 185 | 0.680 |
Why?
|
| Microbial Sensitivity Tests | 4 | 2024 | 170 | 0.670 |
Why?
|
| Middle Aged | 30 | 2019 | 16201 | 0.670 |
Why?
|
| Data Collection | 3 | 2013 | 383 | 0.660 |
Why?
|
| Floors and Floorcoverings | 5 | 2012 | 6 | 0.660 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2019 | 11 | 0.650 |
Why?
|
| Young Adult | 20 | 2019 | 4259 | 0.650 |
Why?
|
| Female | 45 | 2024 | 30596 | 0.640 |
Why?
|
| Models, Molecular | 3 | 2020 | 1109 | 0.640 |
Why?
|
| Thiazolidinediones | 1 | 2019 | 51 | 0.630 |
Why?
|
| Betacoronavirus | 1 | 2020 | 161 | 0.630 |
Why?
|
| Soil | 3 | 2023 | 24 | 0.620 |
Why?
|
| United States | 20 | 2024 | 7496 | 0.610 |
Why?
|
| Male | 39 | 2024 | 27241 | 0.600 |
Why?
|
| Phosphatidylserines | 1 | 2017 | 17 | 0.600 |
Why?
|
| Gene Products, env | 1 | 2017 | 21 | 0.600 |
Why?
|
| Pregnancy Proteins | 1 | 2017 | 17 | 0.600 |
Why?
|
| Aromatase Inhibitors | 3 | 2022 | 25 | 0.600 |
Why?
|
| Aldehyde Reductase | 1 | 2017 | 4 | 0.580 |
Why?
|
| Tuberculosis | 1 | 2020 | 251 | 0.580 |
Why?
|
| Seasons | 4 | 2022 | 138 | 0.580 |
Why?
|
| Molecular Structure | 6 | 2024 | 373 | 0.550 |
Why?
|
| Osteogenesis | 1 | 2017 | 148 | 0.540 |
Why?
|
| Accidents, Home | 1 | 2016 | 13 | 0.540 |
Why?
|
| Rivers | 2 | 2023 | 19 | 0.530 |
Why?
|
| Quality of Life | 1 | 2023 | 1087 | 0.530 |
Why?
|
| Curcumin | 1 | 2017 | 70 | 0.520 |
Why?
|
| India | 5 | 2023 | 155 | 0.510 |
Why?
|
| Athletic Injuries | 1 | 2016 | 69 | 0.500 |
Why?
|
| 3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 1 | 2015 | 3 | 0.500 |
Why?
|
| Azasteroids | 1 | 2015 | 2 | 0.500 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2015 | 6 | 0.500 |
Why?
|
| Dynamin II | 1 | 2014 | 2 | 0.490 |
Why?
|
| Tooth Movement Techniques | 2 | 2023 | 2 | 0.490 |
Why?
|
| Telephone | 2 | 2013 | 125 | 0.490 |
Why?
|
| Animals | 14 | 2024 | 19393 | 0.490 |
Why?
|
| Insulin | 1 | 2019 | 681 | 0.480 |
Why?
|
| Neoplasms | 2 | 2024 | 1222 | 0.480 |
Why?
|
| Public Health | 1 | 2016 | 177 | 0.470 |
Why?
|
| Virus Internalization | 3 | 2024 | 95 | 0.460 |
Why?
|
| Occupational Diseases | 5 | 2011 | 263 | 0.460 |
Why?
|
| Lost to Follow-Up | 1 | 2013 | 6 | 0.450 |
Why?
|
| Orthodontics, Corrective | 1 | 2013 | 1 | 0.450 |
Why?
|
| Safety Management | 5 | 2015 | 143 | 0.450 |
Why?
|
| Bromides | 4 | 2008 | 4 | 0.450 |
Why?
|
| Occupations | 1 | 2013 | 54 | 0.450 |
Why?
|
| Molar | 1 | 2013 | 2 | 0.440 |
Why?
|
| Holidays | 1 | 2013 | 2 | 0.430 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2024 | 805 | 0.420 |
Why?
|
| Workload | 1 | 2013 | 120 | 0.410 |
Why?
|
| Adsorption | 2 | 2023 | 85 | 0.400 |
Why?
|
| Body Mass Index | 2 | 2015 | 904 | 0.400 |
Why?
|
| Aged | 16 | 2019 | 13273 | 0.400 |
Why?
|
| Motor Activity | 1 | 2014 | 342 | 0.390 |
Why?
|
| Sulfites | 2 | 2007 | 7 | 0.370 |
Why?
|
| Potassium Compounds | 3 | 2008 | 9 | 0.370 |
Why?
|
| Protective Clothing | 1 | 2010 | 28 | 0.360 |
Why?
|
| Attitude | 3 | 2019 | 100 | 0.350 |
Why?
|
| Risk Factors | 11 | 2016 | 4993 | 0.350 |
Why?
|
| Internet | 1 | 2013 | 454 | 0.340 |
Why?
|
| Sendai virus | 2 | 2008 | 13 | 0.340 |
Why?
|
| Physician-Patient Relations | 1 | 2013 | 385 | 0.340 |
Why?
|
| Time Factors | 8 | 2018 | 3560 | 0.330 |
Why?
|
| Drug Discovery | 2 | 2020 | 88 | 0.320 |
Why?
|
| Ethanolamine | 1 | 2008 | 3 | 0.320 |
Why?
|
| Macrophages | 1 | 2014 | 992 | 0.320 |
Why?
|
| Nitrophenols | 1 | 2008 | 3 | 0.320 |
Why?
|
| Chymotrypsin | 1 | 2008 | 29 | 0.310 |
Why?
|
| Communication | 1 | 2013 | 530 | 0.310 |
Why?
|
| Binding Sites | 2 | 2021 | 869 | 0.310 |
Why?
|
| Mice | 7 | 2024 | 10140 | 0.310 |
Why?
|
| Alcoholic Beverages | 1 | 2007 | 10 | 0.300 |
Why?
|
| Mercury Compounds | 1 | 2007 | 1 | 0.300 |
Why?
|
| Sulfur Dioxide | 1 | 2007 | 2 | 0.300 |
Why?
|
| Iodides | 1 | 2007 | 4 | 0.300 |
Why?
|
| Bone Resorption | 2 | 2018 | 49 | 0.290 |
Why?
|
| Motor Vehicles | 2 | 2018 | 37 | 0.290 |
Why?
|
| Fractures, Bone | 1 | 2008 | 138 | 0.290 |
Why?
|
| Kinetics | 3 | 2021 | 727 | 0.290 |
Why?
|
| Surface-Active Agents | 1 | 2008 | 112 | 0.290 |
Why?
|
| Bicycling | 2 | 2018 | 24 | 0.290 |
Why?
|
| Cell Differentiation | 3 | 2018 | 1286 | 0.290 |
Why?
|
| Longitudinal Studies | 3 | 2023 | 1210 | 0.280 |
Why?
|
| Beverages | 1 | 2007 | 64 | 0.280 |
Why?
|
| Plastics | 2 | 2023 | 21 | 0.280 |
Why?
|
| Nitrates | 1 | 2006 | 20 | 0.280 |
Why?
|
| Bone and Bones | 2 | 2018 | 154 | 0.270 |
Why?
|
| Back Pain | 1 | 2007 | 51 | 0.270 |
Why?
|
| Prospective Studies | 7 | 2023 | 3058 | 0.270 |
Why?
|
| Cell Membrane | 3 | 2017 | 489 | 0.260 |
Why?
|
| Administrative Personnel | 3 | 2012 | 33 | 0.260 |
Why?
|
| Aromatase | 2 | 2022 | 16 | 0.250 |
Why?
|
| Environment Design | 3 | 2016 | 26 | 0.250 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2024 | 683 | 0.250 |
Why?
|
| Cells, Cultured | 3 | 2018 | 2086 | 0.240 |
Why?
|
| Purines | 1 | 2024 | 38 | 0.240 |
Why?
|
| Thiazoles | 1 | 2024 | 46 | 0.240 |
Why?
|
| Viral Envelope Proteins | 1 | 2005 | 107 | 0.240 |
Why?
|
| Friction | 4 | 2012 | 7 | 0.240 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2021 | 423 | 0.240 |
Why?
|
| Cell Line, Tumor | 3 | 2024 | 1345 | 0.240 |
Why?
|
| Sulfur | 1 | 2024 | 16 | 0.230 |
Why?
|
| Janus Kinase 2 | 1 | 2024 | 13 | 0.230 |
Why?
|
| Janus Kinases | 1 | 2024 | 18 | 0.230 |
Why?
|
| STAT Transcription Factors | 1 | 2024 | 17 | 0.230 |
Why?
|
| Placenta | 1 | 2024 | 59 | 0.230 |
Why?
|
| Surveys and Questionnaires | 5 | 2019 | 2565 | 0.220 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2024 | 192 | 0.220 |
Why?
|
| Ecosystem | 1 | 2023 | 39 | 0.220 |
Why?
|
| Charcoal | 1 | 2023 | 6 | 0.220 |
Why?
|
| Measles Vaccine | 1 | 2023 | 3 | 0.220 |
Why?
|
| Hazardous Substances | 1 | 2023 | 15 | 0.220 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2023 | 6 | 0.220 |
Why?
|
| Molecular Dynamics Simulation | 2 | 2022 | 114 | 0.220 |
Why?
|
| STAT3 Transcription Factor | 1 | 2024 | 68 | 0.220 |
Why?
|
| Nursing Care | 1 | 2003 | 16 | 0.220 |
Why?
|
| United States Food and Drug Administration | 1 | 2024 | 95 | 0.220 |
Why?
|
| Root Resorption | 1 | 2023 | 2 | 0.220 |
Why?
|
| Dental Implants | 1 | 2023 | 3 | 0.220 |
Why?
|
| Workers' Compensation | 6 | 2011 | 75 | 0.220 |
Why?
|
| Breast Neoplasms | 2 | 2022 | 1132 | 0.210 |
Why?
|
| Case Management | 1 | 2003 | 62 | 0.210 |
Why?
|
| Gene Transfer Techniques | 1 | 2005 | 306 | 0.210 |
Why?
|
| Volatile Organic Compounds | 1 | 2022 | 12 | 0.210 |
Why?
|
| Hypoglycemic Agents | 1 | 2024 | 211 | 0.210 |
Why?
|
| Surface Properties | 4 | 2010 | 270 | 0.210 |
Why?
|
| Cell Line | 4 | 2021 | 2009 | 0.210 |
Why?
|
| Povidone-Iodine | 1 | 2021 | 4 | 0.200 |
Why?
|
| Mouthwashes | 1 | 2021 | 6 | 0.200 |
Why?
|
| Methylene Blue | 1 | 2021 | 22 | 0.190 |
Why?
|
| Signal Transduction | 2 | 2024 | 2856 | 0.190 |
Why?
|
| Seaweed | 1 | 2021 | 1 | 0.190 |
Why?
|
| Ulva | 1 | 2021 | 2 | 0.190 |
Why?
|
| Noscapine | 1 | 2021 | 3 | 0.190 |
Why?
|
| Tubulin Modulators | 1 | 2021 | 7 | 0.190 |
Why?
|
| Organelle Size | 1 | 2020 | 1 | 0.190 |
Why?
|
| Dynamic Light Scattering | 1 | 2020 | 3 | 0.190 |
Why?
|
| Ultracentrifugation | 1 | 2020 | 28 | 0.180 |
Why?
|
| Multivariate Analysis | 3 | 2013 | 935 | 0.180 |
Why?
|
| Antibodies, Viral | 1 | 2023 | 306 | 0.180 |
Why?
|
| Amino Sugars | 1 | 2020 | 3 | 0.180 |
Why?
|
| Chromatography, Gel | 1 | 2020 | 65 | 0.180 |
Why?
|
| Vaccination | 1 | 2023 | 331 | 0.180 |
Why?
|
| Immunoprecipitation | 1 | 2020 | 114 | 0.180 |
Why?
|
| Disabled Persons | 1 | 2003 | 204 | 0.180 |
Why?
|
| Tubulin | 1 | 2021 | 73 | 0.180 |
Why?
|
| Immunophenotyping | 1 | 2020 | 191 | 0.180 |
Why?
|
| Calibration | 3 | 2017 | 63 | 0.180 |
Why?
|
| Organ Specificity | 1 | 2020 | 178 | 0.180 |
Why?
|
| Microscopy, Electron | 1 | 2020 | 252 | 0.180 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2020 | 49 | 0.180 |
Why?
|
| Health Surveys | 3 | 2016 | 306 | 0.180 |
Why?
|
| Receptors, Virus | 1 | 2020 | 83 | 0.180 |
Why?
|
| Pyrazoles | 1 | 2020 | 71 | 0.180 |
Why?
|
| Age Factors | 3 | 2013 | 1530 | 0.170 |
Why?
|
| Viral Tropism | 1 | 2020 | 54 | 0.170 |
Why?
|
| Protein Domains | 1 | 2020 | 139 | 0.170 |
Why?
|
| Biofuels | 2 | 2021 | 14 | 0.170 |
Why?
|
| Biomass | 2 | 2021 | 27 | 0.170 |
Why?
|
| Gold | 1 | 2021 | 226 | 0.160 |
Why?
|
| Inservice Training | 2 | 2012 | 81 | 0.160 |
Why?
|
| Perception | 2 | 2012 | 180 | 0.160 |
Why?
|
| Tuberculosis, Lymph Node | 1 | 2018 | 5 | 0.160 |
Why?
|
| Weather | 1 | 2018 | 10 | 0.160 |
Why?
|
| Lighting | 1 | 2018 | 14 | 0.150 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2018 | 29 | 0.150 |
Why?
|
| Infant | 1 | 2023 | 1506 | 0.150 |
Why?
|
| Organizational Culture | 2 | 2019 | 111 | 0.150 |
Why?
|
| Wearable Electronic Devices | 1 | 2019 | 63 | 0.150 |
Why?
|
| Campylobacter Infections | 1 | 2017 | 4 | 0.150 |
Why?
|
| S100 Calcium-Binding Protein A4 | 1 | 2017 | 5 | 0.150 |
Why?
|
| Annexins | 1 | 2017 | 8 | 0.150 |
Why?
|
| RAW 264.7 Cells | 1 | 2018 | 46 | 0.150 |
Why?
|
| Liquid Phase Microextraction | 1 | 2017 | 1 | 0.150 |
Why?
|
| Campylobacter jejuni | 1 | 2017 | 12 | 0.150 |
Why?
|
| Perchlorates | 1 | 2017 | 9 | 0.150 |
Why?
|
| Occupational Exposure | 2 | 2012 | 302 | 0.150 |
Why?
|
| Child | 3 | 2023 | 4225 | 0.150 |
Why?
|
| Bicuspid | 2 | 2015 | 2 | 0.150 |
Why?
|
| Particle Size | 3 | 2016 | 395 | 0.150 |
Why?
|
| Lymph Nodes | 1 | 2018 | 215 | 0.150 |
Why?
|
| Quality Control | 2 | 2007 | 68 | 0.140 |
Why?
|
| Genome, Bacterial | 1 | 2017 | 63 | 0.140 |
Why?
|
| Hematopoiesis | 1 | 2017 | 120 | 0.140 |
Why?
|
| Environment | 1 | 2018 | 124 | 0.140 |
Why?
|
| Membrane Fusion | 1 | 2017 | 73 | 0.140 |
Why?
|
| Mandible | 2 | 2015 | 11 | 0.140 |
Why?
|
| Light | 1 | 2018 | 201 | 0.140 |
Why?
|
| Histidine | 2 | 2008 | 31 | 0.140 |
Why?
|
| Cephalometry | 2 | 2015 | 11 | 0.140 |
Why?
|
| Neoplastic Stem Cells | 1 | 2018 | 200 | 0.140 |
Why?
|
| Bacterial Vaccines | 1 | 2017 | 90 | 0.140 |
Why?
|
| Pregnancy | 1 | 2024 | 2319 | 0.140 |
Why?
|
| Amebicides | 1 | 2016 | 1 | 0.130 |
Why?
|
| Microspheres | 1 | 2016 | 53 | 0.130 |
Why?
|
| Furans | 1 | 2016 | 36 | 0.130 |
Why?
|
| Protein Binding | 1 | 2020 | 1538 | 0.130 |
Why?
|
| Models, Chemical | 2 | 2007 | 133 | 0.130 |
Why?
|
| Maxillofacial Development | 1 | 2015 | 4 | 0.130 |
Why?
|
| Smiling | 1 | 2015 | 2 | 0.130 |
Why?
|
| Polymers | 3 | 2023 | 313 | 0.130 |
Why?
|
| Prostatic Neoplasms | 1 | 2018 | 319 | 0.130 |
Why?
|
| Facial Bones | 1 | 2015 | 12 | 0.130 |
Why?
|
| Face | 1 | 2015 | 34 | 0.130 |
Why?
|
| Pectins | 1 | 2016 | 57 | 0.130 |
Why?
|
| Sensitivity and Specificity | 3 | 2022 | 1089 | 0.130 |
Why?
|
| Bacterial Proteins | 1 | 2021 | 732 | 0.130 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2015 | 48 | 0.130 |
Why?
|
| Insulin Resistance | 1 | 2019 | 398 | 0.130 |
Why?
|
| Cohort Studies | 5 | 2013 | 2434 | 0.120 |
Why?
|
| Lysophosphatidylcholines | 1 | 2014 | 3 | 0.120 |
Why?
|
| Mice, Knockout | 2 | 2017 | 1967 | 0.120 |
Why?
|
| Nerve Tissue Proteins | 1 | 2017 | 419 | 0.120 |
Why?
|
| Dicarboxylic Acids | 1 | 2014 | 3 | 0.120 |
Why?
|
| Analysis of Variance | 1 | 2016 | 584 | 0.120 |
Why?
|
| Molecular Conformation | 1 | 2015 | 132 | 0.120 |
Why?
|
| Carbohydrates | 1 | 2014 | 42 | 0.120 |
Why?
|
| Work Schedule Tolerance | 1 | 2014 | 26 | 0.120 |
Why?
|
| Static Electricity | 1 | 2015 | 163 | 0.120 |
Why?
|
| Cell Communication | 1 | 2014 | 130 | 0.120 |
Why?
|
| Cross-Over Studies | 1 | 2014 | 146 | 0.120 |
Why?
|
| Population Surveillance | 1 | 2015 | 208 | 0.120 |
Why?
|
| Age Distribution | 2 | 2011 | 265 | 0.110 |
Why?
|
| Tooth Extraction | 1 | 2013 | 4 | 0.110 |
Why?
|
| Aggressive Periodontitis | 1 | 2013 | 2 | 0.110 |
Why?
|
| Orthodontic Appliances | 1 | 2013 | 1 | 0.110 |
Why?
|
| Tooth | 1 | 2013 | 4 | 0.110 |
Why?
|
| Exostoses | 1 | 2013 | 3 | 0.110 |
Why?
|
| Malocclusion | 1 | 2013 | 4 | 0.110 |
Why?
|
| Radiography, Panoramic | 1 | 2013 | 3 | 0.110 |
Why?
|
| Brain | 1 | 2021 | 1464 | 0.110 |
Why?
|
| Personnel Staffing and Scheduling | 2 | 2010 | 71 | 0.110 |
Why?
|
| Bone Transplantation | 1 | 2013 | 28 | 0.110 |
Why?
|
| Analgesics, Opioid | 2 | 2009 | 486 | 0.110 |
Why?
|
| Annexin A1 | 1 | 2012 | 3 | 0.110 |
Why?
|
| Self Report | 1 | 2015 | 363 | 0.110 |
Why?
|
| Dynamins | 1 | 2012 | 12 | 0.110 |
Why?
|
| Annexin A5 | 1 | 2012 | 23 | 0.110 |
Why?
|
| Choice Behavior | 1 | 2013 | 76 | 0.110 |
Why?
|
| Occupational Health Services | 1 | 2013 | 39 | 0.110 |
Why?
|
| Return to Work | 1 | 2013 | 23 | 0.110 |
Why?
|
| Sex Factors | 2 | 2015 | 961 | 0.100 |
Why?
|
| Drug Delivery Systems | 1 | 2016 | 302 | 0.100 |
Why?
|
| Rural Population | 1 | 2014 | 189 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2009 | 714 | 0.100 |
Why?
|
| Muscle Development | 1 | 2012 | 53 | 0.100 |
Why?
|
| Life Style | 1 | 2014 | 339 | 0.100 |
Why?
|
| Forests | 2 | 2022 | 6 | 0.100 |
Why?
|
| Japan | 2 | 2022 | 60 | 0.100 |
Why?
|
| Myoblasts | 1 | 2012 | 63 | 0.100 |
Why?
|
| Membrane Proteins | 1 | 2017 | 834 | 0.100 |
Why?
|
| Tibial Meniscus Injuries | 1 | 2011 | 13 | 0.100 |
Why?
|
| Interviews as Topic | 1 | 2013 | 476 | 0.100 |
Why?
|
| Physical Therapy Modalities | 1 | 2011 | 45 | 0.100 |
Why?
|
| Prevalence | 2 | 2013 | 1276 | 0.100 |
Why?
|
| Health Status | 1 | 2014 | 452 | 0.090 |
Why?
|
| Knee Injuries | 1 | 2011 | 47 | 0.090 |
Why?
|
| Ligands | 2 | 2022 | 420 | 0.090 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 788 | 0.090 |
Why?
|
| Hygiene | 1 | 2010 | 11 | 0.090 |
Why?
|
| Epidemiologic Methods | 1 | 2010 | 68 | 0.090 |
Why?
|
| Models, Theoretical | 2 | 2015 | 257 | 0.090 |
Why?
|
| Detergents | 1 | 2010 | 34 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 3139 | 0.090 |
Why?
|
| Protein Conformation | 2 | 2021 | 758 | 0.090 |
Why?
|
| Incisor | 2 | 2023 | 5 | 0.090 |
Why?
|
| Cross-Sectional Studies | 2 | 2014 | 2441 | 0.090 |
Why?
|
| Eye Protective Devices | 1 | 2009 | 3 | 0.080 |
Why?
|
| Eye Injuries | 1 | 2009 | 14 | 0.080 |
Why?
|
| Attention | 1 | 2010 | 153 | 0.080 |
Why?
|
| Chromium | 1 | 2008 | 5 | 0.080 |
Why?
|
| Parainfluenza Virus 3, Human | 1 | 2008 | 5 | 0.080 |
Why?
|
| Follow-Up Studies | 3 | 2010 | 2320 | 0.080 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 845 | 0.080 |
Why?
|
| Reproducibility of Results | 2 | 2017 | 1530 | 0.080 |
Why?
|
| HN Protein | 1 | 2008 | 57 | 0.080 |
Why?
|
| Biocatalysis | 1 | 2008 | 45 | 0.080 |
Why?
|
| Case-Control Studies | 2 | 2008 | 1046 | 0.080 |
Why?
|
| Hydrolysis | 1 | 2008 | 138 | 0.080 |
Why?
|
| Viral Fusion Proteins | 1 | 2008 | 74 | 0.080 |
Why?
|
| Hepatocytes | 2 | 2008 | 185 | 0.080 |
Why?
|
| Microchemistry | 1 | 2007 | 2 | 0.080 |
Why?
|
| Spectrophotometry, Infrared | 1 | 2007 | 27 | 0.070 |
Why?
|
| Electronics | 1 | 2007 | 36 | 0.070 |
Why?
|
| Orthopedic Procedures | 1 | 2007 | 42 | 0.070 |
Why?
|
| Morphine | 1 | 2007 | 52 | 0.070 |
Why?
|
| Potassium | 1 | 2007 | 109 | 0.070 |
Why?
|
| Research Design | 2 | 2007 | 568 | 0.070 |
Why?
|
| Evaluation Studies as Topic | 1 | 2007 | 106 | 0.070 |
Why?
|
| Automation | 1 | 2007 | 58 | 0.070 |
Why?
|
| Food-Processing Industry | 1 | 2006 | 2 | 0.070 |
Why?
|
| Health Care Costs | 1 | 2007 | 199 | 0.060 |
Why?
|
| Health Behavior | 1 | 2009 | 477 | 0.060 |
Why?
|
| Circular Dichroism | 1 | 2005 | 104 | 0.060 |
Why?
|
| Cations | 1 | 2005 | 63 | 0.060 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2005 | 180 | 0.060 |
Why?
|
| Luciferases | 1 | 2005 | 108 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2013 | 5115 | 0.060 |
Why?
|
| Obesity | 1 | 2013 | 1193 | 0.060 |
Why?
|
| Endosomes | 1 | 2005 | 169 | 0.060 |
Why?
|
| Electrocoagulation | 1 | 2004 | 12 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 521 | 0.060 |
Why?
|
| Hyperthermia, Induced | 1 | 2004 | 16 | 0.060 |
Why?
|
| Intervertebral Disc Displacement | 1 | 2004 | 16 | 0.060 |
Why?
|
| Geologic Sediments | 1 | 2023 | 5 | 0.060 |
Why?
|
| Electric Stimulation Therapy | 1 | 2004 | 28 | 0.060 |
Why?
|
| HeLa Cells | 1 | 2005 | 524 | 0.060 |
Why?
|
| Green Fluorescent Proteins | 1 | 2005 | 351 | 0.060 |
Why?
|
| Drug Approval | 1 | 2024 | 27 | 0.060 |
Why?
|
| Microscopy, Fluorescence | 1 | 2005 | 396 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 1 | 2005 | 660 | 0.060 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2005 | 499 | 0.060 |
Why?
|
| Transfection | 1 | 2005 | 667 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 1 | 2005 | 879 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 845 | 0.050 |
Why?
|
| Maxilla | 1 | 2023 | 3 | 0.050 |
Why?
|
| Steryl-Sulfatase | 1 | 2022 | 1 | 0.050 |
Why?
|
| Lipids | 1 | 2005 | 304 | 0.050 |
Why?
|
| Terminology as Topic | 1 | 2003 | 138 | 0.050 |
Why?
|
| Triazoles | 1 | 2022 | 55 | 0.050 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2023 | 69 | 0.050 |
Why?
|
| Administration, Intranasal | 1 | 2021 | 23 | 0.050 |
Why?
|
| Water | 1 | 2023 | 293 | 0.050 |
Why?
|
| Acute Disease | 3 | 2009 | 657 | 0.050 |
Why?
|
| Estrogens | 1 | 2021 | 113 | 0.050 |
Why?
|
| Liver | 1 | 2005 | 760 | 0.050 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2021 | 83 | 0.050 |
Why?
|
| DNA | 1 | 2005 | 783 | 0.050 |
Why?
|
| RNA, Viral | 1 | 2022 | 265 | 0.050 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2021 | 96 | 0.040 |
Why?
|
| Catalysis | 1 | 2021 | 152 | 0.040 |
Why?
|
| Plant Oils | 1 | 2021 | 56 | 0.040 |
Why?
|
| Polyphenols | 1 | 2021 | 52 | 0.040 |
Why?
|
| Hot Temperature | 1 | 2021 | 125 | 0.040 |
Why?
|
| Chitosan | 1 | 2021 | 81 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2005 | 1462 | 0.040 |
Why?
|
| Drug Carriers | 1 | 2021 | 168 | 0.040 |
Why?
|
| Genetic Vectors | 1 | 2005 | 792 | 0.040 |
Why?
|
| Work Performance | 1 | 2019 | 3 | 0.040 |
Why?
|
| Cell Survival | 1 | 2021 | 546 | 0.040 |
Why?
|
| Physical Exertion | 1 | 2019 | 80 | 0.040 |
Why?
|
| Microbiological Techniques | 1 | 2018 | 6 | 0.040 |
Why?
|
| North Dakota | 1 | 2018 | 1 | 0.040 |
Why?
|
| Driving Under the Influence | 1 | 2018 | 3 | 0.040 |
Why?
|
| Missouri | 1 | 2018 | 12 | 0.040 |
Why?
|
| Illinois | 1 | 2018 | 14 | 0.040 |
Why?
|
| Trauma Severity Indices | 1 | 2018 | 38 | 0.040 |
Why?
|
| Lymphadenopathy | 1 | 2018 | 25 | 0.040 |
Why?
|
| New York | 1 | 2018 | 136 | 0.040 |
Why?
|
| Epitopes, B-Lymphocyte | 1 | 2017 | 16 | 0.040 |
Why?
|
| Food Contamination | 1 | 2017 | 21 | 0.040 |
Why?
|
| Limit of Detection | 1 | 2017 | 40 | 0.040 |
Why?
|
| Soil Pollutants | 1 | 2017 | 24 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 173 | 0.040 |
Why?
|
| Milk | 1 | 2017 | 50 | 0.040 |
Why?
|
| Major Histocompatibility Complex | 1 | 2017 | 87 | 0.040 |
Why?
|
| Pandemics | 1 | 2022 | 605 | 0.040 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2018 | 106 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2018 | 489 | 0.040 |
Why?
|
| DNA, Bacterial | 1 | 2018 | 251 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2018 | 492 | 0.040 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2017 | 177 | 0.030 |
Why?
|
| Geographic Information Systems | 1 | 2016 | 21 | 0.030 |
Why?
|
| Proteome | 1 | 2017 | 134 | 0.030 |
Why?
|
| New York City | 1 | 2016 | 75 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2016 | 73 | 0.030 |
Why?
|
| Head Protective Devices | 1 | 2016 | 20 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2021 | 930 | 0.030 |
Why?
|
| Influenza A virus | 1 | 2017 | 111 | 0.030 |
Why?
|
| Epitopes | 1 | 2017 | 298 | 0.030 |
Why?
|
| Zinc Acetate | 1 | 2016 | 1 | 0.030 |
Why?
|
| Gastrointestinal Transit | 1 | 2016 | 6 | 0.030 |
Why?
|
| Drug Liberation | 1 | 2016 | 17 | 0.030 |
Why?
|
| Milk, Human | 1 | 2017 | 94 | 0.030 |
Why?
|
| Gastric Mucosa | 1 | 2016 | 48 | 0.030 |
Why?
|
| Cuspid | 1 | 2015 | 1 | 0.030 |
Why?
|
| Odontometry | 1 | 2015 | 1 | 0.030 |
Why?
|
| Vertical Dimension | 1 | 2015 | 1 | 0.030 |
Why?
|
| Nasal Bone | 1 | 2015 | 4 | 0.030 |
Why?
|
| Sella Turcica | 1 | 2015 | 2 | 0.030 |
Why?
|
| Palate | 1 | 2015 | 9 | 0.030 |
Why?
|
| Computational Biology | 1 | 2017 | 321 | 0.030 |
Why?
|
| Lip | 1 | 2015 | 13 | 0.030 |
Why?
|
| Intestine, Small | 1 | 2016 | 76 | 0.030 |
Why?
|
| Photography | 1 | 2015 | 40 | 0.030 |
Why?
|
| Decision Making | 1 | 2019 | 383 | 0.030 |
Why?
|
| Rabbits | 1 | 2016 | 330 | 0.030 |
Why?
|
| Colon | 1 | 2016 | 134 | 0.030 |
Why?
|
| Video Recording | 1 | 2015 | 123 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2016 | 309 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2016 | 554 | 0.030 |
Why?
|
| Safety | 1 | 2015 | 140 | 0.030 |
Why?
|
| Peptides | 1 | 2017 | 546 | 0.030 |
Why?
|
| Massachusetts | 2 | 2010 | 2093 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2013 | 115 | 0.030 |
Why?
|
| Phosphatidylinositol 4,5-Diphosphate | 1 | 2012 | 16 | 0.030 |
Why?
|
| Climate | 1 | 2012 | 5 | 0.030 |
Why?
|
| Cities | 1 | 2012 | 25 | 0.030 |
Why?
|
| Air Pollution | 1 | 2012 | 34 | 0.030 |
Why?
|
| Food Services | 1 | 2012 | 25 | 0.030 |
Why?
|
| Industry | 1 | 2012 | 61 | 0.030 |
Why?
|
| Logistic Models | 2 | 2007 | 1268 | 0.030 |
Why?
|
| Arthroplasty | 1 | 2011 | 4 | 0.020 |
Why?
|
| Surgical Flaps | 1 | 2013 | 102 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2015 | 624 | 0.020 |
Why?
|
| Arthroscopy | 1 | 2011 | 22 | 0.020 |
Why?
|
| Risk | 1 | 2012 | 377 | 0.020 |
Why?
|
| Menisci, Tibial | 1 | 2011 | 25 | 0.020 |
Why?
|
| Incidence | 1 | 2015 | 1235 | 0.020 |
Why?
|
| Injury Severity Score | 1 | 2011 | 102 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 412 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2011 | 260 | 0.020 |
Why?
|
| Retrospective Studies | 3 | 2007 | 5959 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2016 | 1917 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2010 | 260 | 0.020 |
Why?
|
| Oklahoma | 1 | 2009 | 6 | 0.020 |
Why?
|
| South Carolina | 1 | 2009 | 14 | 0.020 |
Why?
|
| Vermont | 1 | 2009 | 17 | 0.020 |
Why?
|
| Disease Progression | 1 | 2013 | 1025 | 0.020 |
Why?
|
| Body Fluids | 1 | 2008 | 21 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 5062 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 261 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2008 | 252 | 0.020 |
Why?
|
| Risk-Taking | 1 | 2009 | 158 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2008 | 250 | 0.020 |
Why?
|
| Focus Groups | 1 | 2009 | 288 | 0.020 |
Why?
|
| Kidney | 1 | 2008 | 388 | 0.020 |
Why?
|
| Linear Models | 1 | 2007 | 432 | 0.020 |
Why?
|
| Drug Prescriptions | 1 | 2007 | 188 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2009 | 584 | 0.020 |
Why?
|
| Work Capacity Evaluation | 1 | 2004 | 19 | 0.010 |
Why?
|
| New Hampshire | 1 | 2004 | 41 | 0.010 |
Why?
|
| Sick Leave | 1 | 2004 | 21 | 0.010 |
Why?
|
| Narcotics | 1 | 2004 | 50 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2009 | 742 | 0.010 |
Why?
|
| Secondary Prevention | 1 | 2004 | 150 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2007 | 700 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2006 | 1020 | 0.010 |
Why?
|
| Drug Utilization | 1 | 2004 | 223 | 0.010 |
Why?
|
| Recurrence | 1 | 2003 | 569 | 0.010 |
Why?
|
| Prognosis | 1 | 2006 | 1567 | 0.010 |
Why?
|
| Patient Selection | 1 | 2004 | 447 | 0.010 |
Why?
|